Self Study 2024 Release II: Bispecific T-Cell Engager Therapy: Hematologic Malignancies and Solid Tumors
A bispecific T-cell engager (Bite) is a type of bispecific antibody that simultaneously targets an immune-related molecule and a tumor-specific antigen to activate T cell cytotoxicity.1 Since the first FDA approval of a Bite therapy in 2014 with blinatumomab, there have been eight total Bites approved for hematologic and solid malignancies thus far and more being investigated in the pipeline. Unique toxicity profiles characterize these approved Bites. This module provides an overview of the evidence supporting their approved indications and discusses current recommendations and ongoing areas of research for this class of agents.
Course Information
Bispecific T-Cell Engager Therapy: Hematologic Malignancies and Solid Tumors
UAN# 0465-0000-24-109-H01-P
Author: Grace Baek, PharmD, BCOP
Learning Objectives
- Summarize bispecific T-cell engagers’ place in therapy for solid and hematologic malignancies.
- Describe toxicities of bispecific T-cell engagers (Bites).
- Construct a supportive care plan that incorporates evidence-based strategies for preventing and managing therapy-related toxicities of bispecific T-cell engagers (Bites).
- Analyze controversies and future directions associated with bispecific T-cell engager (Bite) therapy.
Knowledge Course for Pharmacists
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.